All In Biotech

Drug Trial Radar · NCT07720284

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 915 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

915

Planned (sponsor's estimate)

Start

Jul 16, 2026

Primary completion

Sep 11, 2030

Study completion Nov 23, 2032

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Jul 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after radical resection. Study details: Duration: \~78 months (6.5 years) from FSI to last subject visit Treatment length: up to \~12 months, depending on randomized arm Visit frequency: every 3 weeks in Arms 1 and 2; every 2-4 weeks per SoC in Arm 3

Conditions

  • High-risk Muscle Invasive Urothelial Carcinoma

Interventions

  • Dato-DXdDrug

    Dato-DXd is an ADC comprised of a recombinant humanised anti-TROP2 IgG1 mAb, MAAP-9001a, which is covalently conjugated via a cleavable drug-linker, MAAA1162a (the complex of MAAA-1181a and a maleimide tetrapeptide linker), using thioether bonds to the topoisomerase I inhibitor DXd.

  • RilvegostomigDrug

    Rilvegostomig is a monovalent, bispecific, humanised, IgG1 mAb engineered with an Fc domain that carries a triple mutation (L234F/L235E/P331S) designed to reduce Fc-mediated effector functions. Rilvegostomig contains 2 distinct paratopes that bind to human TIGIT and PD-1 and inhibit binding to their respective immuno-suppressive ligands.

  • DurvalumabDrug

    A fully human monoclonal antibody that blocks the PD-L1 checkpoint to restore anti-tumor T-cell activity. Durvalumab is approved for Muscle invasive bladder cancer (MIBC) as perioperative regime.

  • NivolumabDrug

    A fully human monoclonal antibody against PD-1, promoting anti-tumor immunity. Approved across many malignancies such as melanoma, NSCLC, renal cell carcinoma, Hodgkin lymphoma, hepatocellular carcinoma, and colorectal cancer (dMMR/MSI-H), often alone or with ipilimumab. It's used in several cancers, notably unresectable stage III non-small cell lung cancer after chemoradiation and extensive-stage small cell lung cancer in combination regimens, among others, and is also approved for patients with muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence in the adjuvant setting.

  • PembrolizumabDrug

    A humanized monoclonal antibody targeting PD-1, enhancing T-cell-mediated immune responses against tumors. Indications span multiple cancers including melanoma, NSCLC, head and neck squamous cell carcinoma, urothelial carcinoma, MSI-H/dMMR tumors, and more.

  • Enfortumab vedotinDrug

    An antibody-drug conjugate (ADC) comprised of a fully human anti-Nectin-4 IgG1 monoclonal antibody, linked via a protease-cleavable maleimide-based linker to the microtubule-disrupting agent monomethyl auristatin E (MMAE), which is conjugated through thioether bonds. Upon binding to Nectin-4-expressing cells, the ADC is internalized and releases MMAE, leading to disruption of microtubule dynamics and subsequent tumor cell death. Enfortumab vedotin is approved in urothelial cancers.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate the superiority of Dato-DXd + rilvegostomig (Arm 1) relative to SoC (Arm 3) by assessment of disease-free survival (DFS) (based on Investigator assessments).Time frame: From randomisation until disease recurrence as assessed by investigator or death due to any cause (anticipated to be up to 49 months after the first subject in).

Locations

160 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site

    Hot Springs, Arkansas · Not yet recruiting

  • Research Site

    Little Rock, Arkansas · Not yet recruiting

  • Research Site

    Little Rock, Arkansas · Not yet recruiting

  • Research Site

    San Francisco, California · Not yet recruiting

  • Research Site

    Chicago, Illinois · Withdrawn

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Kansas City, Missouri · Not yet recruiting

  • Research Site

    Lincoln, Nebraska · Not yet recruiting

  • Research Site

    Omaha, Nebraska · Not yet recruiting

  • Research Site

    Albany, New York · Not yet recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Myrtle Beach, South Carolina · Not yet recruiting

  • Research Site

    Nashville, Tennessee · Not yet recruiting

  • Research Site

    Dallas, Texas · Not yet recruiting

  • Research Site

    Falls Church, Virginia · Not yet recruiting

  • Research Site

    Seattle, Washington · Not yet recruiting

  • Research Site

    Tacoma, Washington · Not yet recruiting

  • Research Site

    Milwaukee, Wisconsin · Not yet recruiting

  • Research Site

    Auchenflower, Australia · Withdrawn

  • Research Site

    Ballarat, Australia · Not yet recruiting

  • Research Site

    Clayton, Australia · Not yet recruiting

  • Research Site

    Darlinghurst, Australia · Not yet recruiting

  • Research Site

    Elizabeth Vale, Australia · Not yet recruiting

  • Research Site

    South Brisbane, Australia · Not yet recruiting

  • Research Site

    St Albans, Australia · Withdrawn

  • Research Site

    Barretos, Brazil · Not yet recruiting

  • Research Site

    Curitiba, Brazil · Not yet recruiting

  • Research Site

    Salvador, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    Calgary, Alberta, Canada · Not yet recruiting

  • Research Site

    Abbotsford British Columbia, British Columbia, Canada · Not yet recruiting

  • Research Site

    Barrie, Ontario, Canada · Recruiting

  • Research Site

    Hamilton, Ontario, Canada · Recruiting

  • Research Site

    Kingston, Ontario, Canada · Not yet recruiting

  • Research Site

    London, Ontario, Canada · Not yet recruiting

  • Research Site

    Mississauga, Ontario, Canada · Not yet recruiting

  • Research Site

    Montreal, Quebec, Canada · Not yet recruiting

  • Research Site

    Montreal, Quebec, Canada · Not yet recruiting

Showing 40 of 160 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.